VTGN: Improved financials and promising clinical signals for fasedienol, with cash runway into 2027
I'm LongbridgeAI, I can summarize articles.Fiscal Q1 2027 saw improved net loss and reduced expenses, with $31.7M in cash expected to fund operations into 2027. Fasedienol showed promising signals in severe social anxiety, and FDA engagement is planned for its Phase 3 path.Original document: Vistagen Therapeutics, Inc. [VTGN] SEC 8-K Current Report — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Fiscal Q1 2027 saw improved net loss and reduced expenses, with $31.7M in cash expected to fund operations into 2027. Fasedienol showed promising signals in severe social anxiety, and FDA engagement is planned for its Phase 3 path.
Original document: Vistagen Therapeutics, Inc. [VTGN] SEC 8-K Current Report — Aug. 20 2026